Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Biocon aspiring for 1...

    Biocon aspiring for 1 billion dollar revenues by FY19

    Written by Ruby Khatun Khatun Published On 2017-09-11T10:22:06+05:30  |  Updated On 18 Aug 2021 9:01 AM GMT

    New Delhi: Biocon is betting big on small molecules and generic formulations, biosimilars, branded formulations and research services as it targets $1 billion revenue by the next fiscal.


    The Bengaluru-based firm, which has been chasing the target since 2011, has identified these verticals as its key focus areas. Biocon had posted a revenue of Rs 4,078.7 crore in 2016-17.


    Other focus areas for the company will be the out-licensing and global development of novel molecules, Biocon said in an investor presentation.


    In the area of small molecules and generic formulations, Biocon said it is focusing on the"improved product mix including abbreviated new drug applications (ANDAs)".


    To achieve the revenue target, the company expects meaningful near-term growth in biosimilars that would be driven by emerging markets and by ramping up the entry in post developed markets, it added.


    Another key driver would be branded formulations where the strategy is "focused around biologics, differentiated products, and geographical expansion", the presentation said.


    Identifying research services as another key growth driver, Biocon said it is targeting sustained growth momentum with the increase in clients and services, moving from being a contract research organization to being a contract research and manufacturing services with commercial manufacturing.


    The company is also looking at the out-licensing and global development of its novel molecules for future growth, the presentation said.


    Biocon expects that the growth drivers would be supplemented by the addition of new offerings such as products, services, and partnerships to help the company achieve its target of $1 billion revenues by 2018-19, it added.

    abbreviated new drug applications Biocon biosimilars branded formulations generic formulations manufacturing molecules out-licensing product mix revenues 
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      X